3-[[2-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]-2-oxoethyl]amino]benzamide

3-[[2-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]-2-oxoethyl]amino]benzamide is a 2-(3,4-dimethoxyphenyl)ethylamine derivative for oral administration at an exploratory stage of new drug development.

Signaling Pathways >> Others >> Others

Research Areas >> Others

The hydrochloride form shows incompatibility with the excipients used for oral dosage forms. There are several crystal forms of the free base, namely, alpha-anhydrate, beta-anhydrate, monohydrate, and trihydrate. The trihydrate form is unstable. The degree of crystallinity of the beta-anhydrate form is difficult to control. The monohydrate form is difficult to manufacture with constant quality. The serum levels of the compounds in rats are almost related to the dissolution rates in the JP 1st disintegration medium from the discs. The serum level of alpha-anhydrate is the lowest[1].

[1]. Morita M, et al. Preliminary preformulation studies of a 2-(3,4-dimethoxyphenyl)ethylamine derivative for oral administration at an exploratory stage of new drug development. Chem Pharm Bull (Tokyo). 1995 Mar;43(3):476-82.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline